Portfolio Design Labs LLC Buys Shares of 10,911 Boston Scientific Co. (NYSE:BSX)

Portfolio Design Labs LLC acquired a new position in Boston Scientific Co. (NYSE:BSX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,911 shares of the medical equipment provider's stock, valued at approximately $975,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Quent Capital LLC grew its holdings in shares of Boston Scientific by 29.6% during the 4th quarter. Quent Capital LLC now owns 3,256 shares of the medical equipment provider's stock worth $291,000 after purchasing an additional 744 shares during the period. Essex Financial Services Inc. lifted its position in Boston Scientific by 13.1% in the fourth quarter. Essex Financial Services Inc. now owns 2,621 shares of the medical equipment provider's stock valued at $234,000 after buying an additional 303 shares during the last quarter. BostonPremier Wealth LLC purchased a new position in Boston Scientific during the fourth quarter worth about $226,000. Focus Financial Network Inc. increased its position in shares of Boston Scientific by 9.8% during the fourth quarter. Focus Financial Network Inc. now owns 18,121 shares of the medical equipment provider's stock valued at $1,619,000 after acquiring an additional 1,615 shares during the last quarter. Finally, Sapient Capital LLC raised its stake in shares of Boston Scientific by 0.7% in the 4th quarter. Sapient Capital LLC now owns 134,984 shares of the medical equipment provider's stock valued at $12,057,000 after acquiring an additional 964 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now owns 39,398 shares of the company's stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares of the company's stock, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,830 shares of company stock worth $5,149,969. 0.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on BSX shares. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, January 29th. Canaccord Genuity Group raised their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Mizuho boosted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Morgan Stanley raised their target price on Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Finally, UBS Group boosted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $107.39.

Boston Scientific Stock Down 0.2 %

Boston Scientific stock traded down $0.18 during midday trading on Wednesday, reaching $105.80. The company's stock had a trading volume of 5,456,226 shares, compared to its average volume of 6,164,861. The company has a market cap of $155.93 billion, a P/E ratio of 84.64, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The business has a 50-day simple moving average of $95.50 and a 200-day simple moving average of $87.72. Boston Scientific Co. has a fifty-two week low of $64.54 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. On average, research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.